HeartBeam rises on FDA clearance for heart-monitoring device
16/12/2024 14:07
** Shares of medical device maker HeartBeam BEAT.O rise
9.3% to $3.55 in premarket trading
** Company says the U.S. FDA cleared its device that can
record the heart's electrical activity and help in detecting
irregular heartbeats
** Says the credit card-sized device, when placed on the
patient's chest, works by capturing the signals, which are then
processed and sent to a physician for review
** Up to last close, stock up 32.8% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on HeartBeam
See all newsBrief: Heartbeam Receives FDA Breakthrough Device Designation For Heart Attack Assessment
Brief: HeartBeam Will Not Build Large Commercial Organization For Arrhythmia Indication
Brief: Heartbeam, Inc. Enters Into At-The-Market Equity Offering Sales Agreement For Up To $25 Million In Common Stock
HeartBeam, Inc. reports results for the quarter ended June 30 - Earnings Summary
HeartBeam Q2 loss per share narrows; co lowers FY net operating cash outflow guidance